Table 3 Subgroup analysis of medical expenditure for lung cancer diagnosis and treatment per case
From: Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey
Variable | Expenditure per case during 2002–2011, CNY Mean (95% CI) | Value | P | Expenditure per case during 2009–2011, CNY Mean (95% CI) | Value | P |
|---|---|---|---|---|---|---|
Overall | 39,015(38,401–39,629) | 44,809 (43,656–45,962) | ||||
Region | 378.00 | < 0.001a | 223.69 | < 0.001a | ||
East | 43,100(42,185–44,015) | 51,414 (49,721–53,107) | ||||
Central | 38,003(37,014–38,992) | 46,151 (44,045–48,257) | ||||
West | 31,948(30,701–33,196) | 32,439 (30,347–34,531) | ||||
Hospital type | − 17.94 | < 0.001b | − 4.61 | < 0.001b | ||
General hospital | 32,043(31,054–33,031) | 43,182 (41,131–45,232) | ||||
Specialized hospital | 42,028(41,266–42,790) | 45,637 (44,245–47,029) | ||||
Hospital level | 19.95 | < 0.001b | 14.83 | < 0.001b | ||
3 A | 40,173(39,531–40,815) | 46,192 (45,000–47,383) | ||||
3 B or less | 23,246(21,457–25,034) | 18,660 (15,710–21,611) | ||||
Number of clinical visits per case | 1671.52 | < 0.001a | 408.03 | < 0.001a | ||
1 | 23,870(23,380–24,360) | 26,696 (25,698–27,693) | ||||
2 | 45,966(44,430–47,501) | 48,008 (45,276–50,739) | ||||
3 | 59,332(57,165–61,499) | 59,473 (55,859–63,087) | ||||
4 + | 71,323(69,462–73,183) | 70,397 (67,671–73,122) | ||||
Gender | 6.18 | < 0.001b | 1.57 | 0.116b | ||
Male | 40,035(39,287–40,784) | 45,285 (43,885–46,684) | ||||
Female | 36,649(35,582–37,715) | 43,766 (41,732–45,799) | ||||
Age at diagnosis, years | 8.35 | < 0.001a | 9.41 | < 0.001a | ||
< 45 | 38,198(36,210–40,186) | 43,750 (39,551–47,949) | ||||
45–54 | 39,202(37,913–40,491) | 47,391 (44,746–50,036) | ||||
55–64 | 40,139(39,070–41,208) | 46,288 (44,401–48,176) | ||||
≥ 65 | 38,068(37,026–39,110) | 42,152 (40,236–44,068) | ||||
Pathological type | 67.80 | < 0.001b | 32.21 | < 0.001b | ||
Squamous cell carcinoma | 39,154(38,189–40,119) | 47,491 (45,509–49,473) | ||||
Adenocarcinoma | 43,416(42,280–44,552) | 50,693 (48,676–52,710) | ||||
Others | 36,854(35,548–38,161) | 42,886 (40,259–45,474) | ||||
Clinical stage | 21.03 | < 0.001a | 21.81 | < 0.001a | ||
I | 36,413(35,307–37,520) | 42,960 (40,820–45,101) | ||||
II | 36,713(35,357–38,070) | 43,851 (41,068–46,635) | ||||
III | 41,069(39,907–42,232) | 45,861 (43,754–47,968) | ||||
IV | 39,904(38,694–41,115) | 42,914 (40,703–45,125) |